Comparative Pharmacology
Head-to-head clinical analysis: EMTRIVA versus LAMIVUDINE NEVIRAPINE AND ZIDOVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRIVA versus LAMIVUDINE NEVIRAPINE AND ZIDOVUDINE.
EMTRIVA vs LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase by competing with natural nucleosides and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase and inhibits RNA-dependent DNA polymerase activity.
Emtricitabine 200 mg orally once daily.
One tablet (lamivudine 150 mg, nevirapine 200 mg, zidovudine 300 mg) orally twice daily.
None Documented
None Documented
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Lamivudine: 5-7 hours; Nevirapine: 25-30 hours (single dose), 40-45 hours with multiple dosing due to autoinduction; Zidovudine: 0.5-3 hours (mean 1.1 hours). Clinical context: Dosing interval adjusted for renal/hepatic function.
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Lamivudine: >70% unchanged in urine via glomerular filtration and active tubular secretion. Nevirapine: ~80% in urine as glucuronide conjugates and metabolites, <5% unchanged. Zidovudine: ~75% as metabolites (primarily zidovudine glucuronide) in urine, <20% unchanged.
Category C
Category A/B
Antiretroviral, NRTI
NRTI